医学
FOXP3型
白细胞介素2受体
流式细胞术
生物标志物
抗体
细胞因子
免疫学
内科学
临床终点
格林-巴利综合征
调节性T细胞
前瞻性队列研究
CD8型
胃肠病学
免疫系统
临床试验
T细胞
化学
生物化学
作者
Israt Jahan,Rasel Ahmed,Jigishu Ahmed,Md Nure Alam Afsar,Pritha Promita Biswas,Sarah Khurshid,Quazi Deen Mohammad,Hubert P. Endtz,Ruth Huizinga,Bart C. Jacobs,Zhahirul Islam
摘要
BACKGROUND AND AIMS: Intravenous immunoglobulin (IVIg) is the primary treatment for Guillain-Barré syndrome (GBS), yet its immunological mechanisms underlying variable clinical outcomes remain unclear. This study investigated the immunomodulatory effect of IVIg on regulatory T cells (Tregs), cytokines, and their association with treatment response and clinical outcomes. METHODS: Treg percentages, cytokine production (IL-10, TNF-α, IFN-γ, and IL-12), and serum C3 levels were measured using flow cytometry, Luminex assay, and turbidimetric methods, respectively. Treatment response was defined as ≥ 1-point GBS-disability score improvement during evaluation. RESULTS: Tregs frequencies compared to HCs (p = 0.006), which were inversely associated with serum C3 levels (p = 0.003) during the acute phase. At 4 weeks post-onset, patients with normal C3 levels (90-180 mg/dL) exhibited higher Treg frequencies (p = 0.005) compared to acute GBS, whereas patients with persistently elevated C3 levels showed reduced Treg percentage (p = 0.009). Among I VIg-treated patients, Tregs significantly increased at 2 and 4 weeks post-treatment, alongside significantly higher IL-10 and lower TNF-α, IFN-γ, and IL-12 levels at 4 weeks. However, patients with supportive care showed no such changes in Tregs and cytokine levels. Furthermore, Tregs elevated significantly in patients responsive to IVIg at 2 and 4 weeks (p < 0.05), but not in non-responsive or supportive care patients. INTERPRETATION: Tregs and altering cytokines and serum C3 levels, which are associated with clinical improvement. These findings indicate Tregs as potential biomarkers for monitoring initial clinical response to IVIg in GBS.
科研通智能强力驱动
Strongly Powered by AbleSci AI